214 related articles for article (PubMed ID: 21081657)
1. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
[TBL] [Abstract][Full Text] [Related]
4. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
5. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Pusztai L; Wagner P; Ibrahim N; Rivera E; Theriault R; Booser D; Symmans FW; Wong F; Blumenschein G; Fleming DR; Rouzier R; Boniface G; Hortobagyi GN
Cancer; 2005 Aug; 104(4):682-91. PubMed ID: 15986399
[TBL] [Abstract][Full Text] [Related]
7. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
van Zuylen L; Sparreboom A; van der Gaast A; Nooter K; Eskens FA; Brouwer E; Bol CJ; de Vries R; Palmer PA; Verweij J
Eur J Cancer; 2002 May; 38(8):1090-9. PubMed ID: 12008197
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
[TBL] [Abstract][Full Text] [Related]
9. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
10. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
[TBL] [Abstract][Full Text] [Related]
12. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Fox E; Bates SE
Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Borghaei H; Alpaugh K; Hedlund G; Forsberg G; Langer C; Rogatko A; Hawkins R; Dueland S; Lassen U; Cohen RB
J Clin Oncol; 2009 Sep; 27(25):4116-23. PubMed ID: 19636016
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Fracasso PM; Goldstein LJ; de Alwis DP; Rader JS; Arquette MA; Goodner SA; Wright LP; Fears CL; Gazak RJ; Andre VA; Burgess MF; Slapak CA; Schellens JH
Clin Cancer Res; 2004 Nov; 10(21):7220-8. PubMed ID: 15534095
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Diamond JR; Goff B; Forster MD; Bendell JC; Britten CD; Gordon MS; Gabra H; Waterhouse DM; Poole M; Ross Camidge D; Hamilton E; Moore KM
Invest New Drugs; 2017 Oct; 35(5):627-633. PubMed ID: 28283779
[TBL] [Abstract][Full Text] [Related]
18. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration.
Matzneller P; Kussmann M; Eberl S; Maier-Salamon A; Jäger W; Bauer M; Langer O; Zeitlinger M; Poeppl W
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):599-606. PubMed ID: 29616423
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.
Miettinen S; Grènman S; Ylikomi T
Anticancer Drugs; 2009 Apr; 20(4):267-76. PubMed ID: 19262372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]